Autoantibodies Are Early Diabetes Warning Signs
|
By LabMedica International staff writers Posted on 09 Mar 2015 |
Detection of autoantibodies directed against pancreatic islet cells can be used to predict the likelihood of a child developing type I diabetes.
Investigators at Lund University (Sweden) recruited 8,503 participants in the TEDDY (The Environmental Determinants of Diabetes in the Young) study to take part in their autoantibody experiment. The TEDDY study, funded by the [US] National Institutes of Health, involved 8,600 children from Sweden, the USA, Finland, and Germany, who showed an increased hereditary risk of type I diabetes, detected at birth through tests on umbilical cord blood.
Infants with HLA-DR high-risk genotypes (DR3/4, DR4/4, DR4/8, and DR3/3) from the TEDDY group were prospectively followed with standardized autoantibody assessments quarterly throughout the first four years of life and then semiannually thereafter. The Lund University researchers reported that 6.5% of the participating children had their first autoantibody before the age of six. In 44% of cases, they only had an autoantibody against insulin (IAA). Most of them had this by the age of one to two years. In 38% of cases, GAD65 autoantibodies (GADA) were detected. The numbers increased until the age of two and then remained constant. In 14% of cases both autoantibodies were found at the same time, with a peak at the age of two to three.
The investigators concluded from the results that there were three ways to predict development of type I diabetes: 1) if the autoantibody first discovered attacked insulin (IAA); 2) if the first autoantibody targeted GAD65 (GADA), a protein inside the insulin-producing cells; or 3) if both autoantibodies were first found together.
"In the TEDDY study we have found that autoantibodies often appear during the first few years of life", said contributing author Dr. Åke Lernmark, professor of experimental diabetes at Lund University. "If a second autoantibody is detected later, then the person will get diabetes - but it may take up to 20 years. In TEDDY, 40% of these children had already developed diabetes. It is possible that there are two different diseases involved. Perhaps one virus triggers the autoantibodies against insulin and another one the autoantibodies against GAD65."
The study was published in the February 10, 2015, online edition of the journal Diabetologia.
Related Links:
Lund University
Investigators at Lund University (Sweden) recruited 8,503 participants in the TEDDY (The Environmental Determinants of Diabetes in the Young) study to take part in their autoantibody experiment. The TEDDY study, funded by the [US] National Institutes of Health, involved 8,600 children from Sweden, the USA, Finland, and Germany, who showed an increased hereditary risk of type I diabetes, detected at birth through tests on umbilical cord blood.
Infants with HLA-DR high-risk genotypes (DR3/4, DR4/4, DR4/8, and DR3/3) from the TEDDY group were prospectively followed with standardized autoantibody assessments quarterly throughout the first four years of life and then semiannually thereafter. The Lund University researchers reported that 6.5% of the participating children had their first autoantibody before the age of six. In 44% of cases, they only had an autoantibody against insulin (IAA). Most of them had this by the age of one to two years. In 38% of cases, GAD65 autoantibodies (GADA) were detected. The numbers increased until the age of two and then remained constant. In 14% of cases both autoantibodies were found at the same time, with a peak at the age of two to three.
The investigators concluded from the results that there were three ways to predict development of type I diabetes: 1) if the autoantibody first discovered attacked insulin (IAA); 2) if the first autoantibody targeted GAD65 (GADA), a protein inside the insulin-producing cells; or 3) if both autoantibodies were first found together.
"In the TEDDY study we have found that autoantibodies often appear during the first few years of life", said contributing author Dr. Åke Lernmark, professor of experimental diabetes at Lund University. "If a second autoantibody is detected later, then the person will get diabetes - but it may take up to 20 years. In TEDDY, 40% of these children had already developed diabetes. It is possible that there are two different diseases involved. Perhaps one virus triggers the autoantibodies against insulin and another one the autoantibodies against GAD65."
The study was published in the February 10, 2015, online edition of the journal Diabetologia.
Related Links:
Lund University
Latest Clinical Chem. News
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
- Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection
- Breath Test Could Help Detect Blood Cancers
- ML-Powered Gas Sensors to Detect Pathogens and AMR at POC
- Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation
- Skin Swabs Could Detect Parkinson’s Years Before Symptoms Appear
- New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs

- New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
- Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Channels
Molecular Diagnostics
view channel
Blood Protein Profiles Predict Mortality Risk for Earlier Medical Intervention
Elevated levels of specific proteins in the blood can signal increased risk of mortality, according to new evidence showing that five proteins involved in cancer, inflammation, and cell regulation strongly... Read more
First Of Its Kind Blood Test Detects Gastric Cancer in Asymptomatic Patients
Each year, over 1 million people worldwide are diagnosed with gastric (stomach) cancer, and over 800,000 people die of the disease. It is among the top 5 deadliest cancers worldwide for both men and women.... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read more
Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. Despite TB infecting 10 million people yearly, the... Read more
15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
Distinguishing minor childhood illnesses from potentially life-threatening infections such as sepsis or meningitis remains a major challenge in emergency care. Traditional tests can take hours, leaving... Read more
High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read morePathology
view channel
AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
Complex digital biopsy images that typically take an expert pathologist up to 20 minutes to assess can now be analyzed in about one minute using a new artificial intelligence (AI) tool. The technology... Read more
Diagnostic Technology Performs Rapid Biofluid Analysis Using Single Droplet
Diagnosing disease typically requires milliliters of blood drawn at clinics, depending on needles, laboratory infrastructure, and trained personnel. This process is often painful, resource-intensive, and... Read moreTechnology
view channel
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read more
AI-Powered Biosensor Technology to Enable Breath Test for Lung Cancer Detection
Detecting lung cancer early remains one of the biggest challenges in oncology, largely because current tools are invasive, expensive, or unable to identify the disease in its earliest phases.... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








